Mobia Medical, Inc MOBI
- Market cap
- $293.3M
- P/E
- 0.0×
Follow MOBI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 167 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 16 | 32 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | 79.59% | 81.07% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | — | (25) | (46) |
EBT
|
|||
| — | — | — | — | — | — | — | — | (157.18%) | (145.10%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (25) | (46) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 27.21 | 37.74 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (42.79) | (54.77) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (42.29) | (53.82) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.07) | (0.43) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (42.36) | (54.25) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 15.29 | 34.16 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (0.04) | (0.04) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | (24) | (46) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (24) | (46) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 17 | 36 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 7 | 7 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (8) | (26) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 9 | 29 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (132.40%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (1,198.77%) | (1,140.09%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 36.21% |
ROE
|
|||
Mobia Medical, Inc (MOBI) key facts
- Mobia Medical, Inc’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 104.8% from fiscal 2024.
- Mobia Medical, Inc reported a net loss of $46.5 million, or a loss of $54.77 per share, for fiscal 2025.
- As of September 25, 2026, MOBI traded at $9.06, a market capitalization of $293.3 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.5× sales.
- Return on equity was 36.2% and debt-to-equity 0.04.
Mobia Medical, Inc (MOBI) Latest News
28 Aug
Mobia Medical announces addition of Paired VNS to updated AHA stroke guidelines. Guideline inclusion can drive wider adoption and revenue for MOBI's core Paired VNS therapy.
18 Aug
Mobia Medical (MOBI) released its Q2 2026 earnings call transcript covering quarterly results, financial metrics, and management commentary on operations and outlook. Earnings call delivers financial updates that can moderately shift investor sentiment and short-term valuation without guaranteeing major strategic shifts.
12 Aug
Mobia Medical Inc posted 102% revenue growth in Q2 2026 driven by IPO proceeds. IPO-fueled revenue doubling signals major trajectory shift for Mobia Medical Inc.
11 Aug
Mobia Medical discussed Q2 financial results, revenue figures, operational updates and forward guidance during its earnings call. Quarterly earnings data and guidance directly affect near-term valuation and trading activity.
Mobia Medical, Inc (MOBI) reported its second quarter 2026 financial results. Quarterly earnings releases deliver performance data that can shift near-term valuation and trading activity.
14 Jul
Mobia Medical published two-year VNS-REHAB trial data confirming durable and continued stroke recovery with Vivistim Paired VNS Therapy. Positive long-term trial data strengthens product validation and supports commercial adoption for Vivistim therapy.
2 Jul
Mobia Medical's Vivistim procedure maintains assignment to New Technology APC 1580 in the CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule. APC 1580 retention secures ongoing favorable reimbursement for Vivistim and bolsters revenue stability.
2 Jun
BofA initiates coverage on Mobia Medical (MOBI) and states the company is poised for commercial expansion. BofA coverage launch citing commercial expansion readiness points to major growth catalyst and sentiment shift for MOBI.
7 May
Mobia Medical, Inc. (MOBI) priced its initial public offering. IPO pricing enables Mobia Medical to access public capital markets and shifts its ownership and reporting structure.